Global News

Regeneron, Adicet Bio collaborate on immune cell therapeutics

Wednesday, August 3, 2016

Regeneron Pharmaceuticals and Adicet Bio have announced a collaboration and licensing agreement to develop next-generation engineered immune cell therapeutics. The companies plan to engineer immune cells with fully human chimeric antigen receptors (CARs) and T-cell receptors (TCRs) directed to disease-specific cell surface antigens in order to enable the precise engagement and killing of tumor cells. The collaboration is intended to generate multiple clinical product candidates for various hematological and solid tumor cancers.

[Read More]

Altimmune receives $120M BARDA contract for Anthrax vaccine candidate Nasoshield

Wednesday, August 3, 2016

Altimmune, a clinical stage immunotherapeutic company, was awarded a contract valued at up to $120.2 million over five years from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to fund the clinical development of NasoShield, its first-in-class anthrax vaccine candidate. Under BARDA contract HHSO100201600008C, Altimmune has been awarded $14.3 million under the base contract to fund its phase I trial for NasoShield, and options to receive up to an additional $105.9 million to fund further preclinical, clinical and manufacturing development activities. 

[Read More]

Quintiles, DaVita Clinical Research partner

Tuesday, August 2, 2016

Quintiles, a provider of product development and integrated healthcare services, and DaVita Clinical Research, a wholly-owned subsidiary of DaVita HealthCare Partners, a leader in kidney care, have announced a global strategic alliance. The alliance combines DaVita’s clinical care and expansive footprint of research sites with Quintiles’ operational delivery and therapeutic expertise in clinical trials.

[Read More]

BTC Network rebrands, acquires Novex Clinical Research

Tuesday, August 2, 2016

BTC Network, a fully integrated network of clinical research sites in the U.S., has strengthened its site operations with the recent acquisition of Novex Clinical Research, a multi-specialty research practice in New Bedford, Massachusetts. As a result of the deal, Novex Clinical Research will be the first clinical research site to be owned and operated under the BTC Network umbrella. It will strengthen BTC Network’s expertise and commitment to therapeutic areas such as psychiatry, neurology, pain, and internal medicine.

[Read More]